PR Newswire SARASOTA, Fla., Oct. 21, 2024 SARASOTA, Fla., Oct. 21, 2024 /PRNewswire/ -- Prostate cancer is the most common non-skin cancer in men in the US, and the 4th most common tumor diagnosed worldwide. As part of its commitment to ...
PR Newswire WINSTON-SALEM, N.C., Oct. 21, 2024 WINSTON-SALEM, N.C., Oct. 21, 2024 /PRNewswire/ -- mPATH® Health, a digital health company dedicated to improving cancer screening, is thrilled to announce the successful closure of $3 million ...
PR Newswire BALTIMORE and PALO ALTO, Calif., Oct. 21, 2024 Provider of Accessible Blood-Based Tests for Cancer Detection Highlights Results of Clinical Trial in Preeminent Peer-Reviewed Publication BALTIMORE and PALO ALTO, Calif., Oct. ...
PR Newswire NASHVILLE, Tenn. and GOLDSBORO, N.C., Oct. 21, 2024 NASHVILLE, Tenn. and GOLDSBORO, N.C., Oct. 21, 2024 /PRNewswire/ -- OneOncology, a physician-led national platform advancing independent oncology practices, and Southeastern ...
PR Newswire TAOYUAN, Oct. 20, 2024 Cellular Therapy Emerges as a Front-Runner in Medical Innovation TAOYUAN, Oct. 20, 2024 /PRNewswire/ -- Cellular therapy, a revolutionary approach where cells are manipulated outside the body and then ...
PR Newswire TUCSON, Ariz., Oct. 18, 2024 TUCSON, Ariz., Oct. 18, 2024 /PRNewswire/ -- Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the VENTANA? CLDN18 (43-14A) RxDx Assay is the first U.S. Food and Drug Administration (FDA) ...
PR Newswire TOKYO, Oct. 18, 2024 VYLOY is the first and only CLDN18.2-targeted treatment approved in the U.S. for adults with advanced gastric and gastroesophageal junction cancer whose tumors are CLDN18.2 positive TOKYO, Oct. 18, 2024 ...
Canada NewsWire OTTAWA, ON, Oct. 18, 2024 Deal fails to include measures to reduce smoking OTTAWA, ON, Oct. 18, 2024 /CNW/ - The Canadian Cancer Society (CCS) is strongly criticizing a proposed settlement of tobacco lawsuits announced ...
PR Newswire LORTON, Va., Oct. 18, 2024 LORTON, Va., Oct. 18, 2024 /PRNewswire/ -- Olight, a brand committed to becoming a global leader in mid-to-high-end flashlights, introduced its charity initiatives dedicated to supporting breast cancer ...
PR Newswire EAST HANOVER, N.J., Oct. 18, 2024 EAST HANOVER, N.J., Oct. 18, 2024 /PRNewswire/ -- Novartis announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a ...
Immunotherapy is a promising treatment that harnesses the immune system to combat cancer, but its effectiveness has been limited in treating gastrointestinal cancers. ...
Adding immunotherapy to neoadjuvant chemoradiation can improve survival and enable surgery in esophageal cancer, reveals research results published in a journal of the American Association for Cancer Research. Bottom Line In patients with unresectable, locally advanced esophageal cancer, the combination of radiation, chemotherapy, and immunotherapy increased the likelihood of tumors becoming surgically removable, leading to significantly better ...
A small clinical trial has shown encouraging outcomes for patients with triple-negative breast cancer who were treated with an experimental vaccine aimed at preventing tumor...
Cannabis consumption can wreak havoc on our cellular health, significantly increasing the risk of developing deadly cancerous tumors. In the study, published in the scientific journal Addiction Biology, cannabis is described as a ...
An investigational white button mushroom supplement shows promise in slowing and even preventing the spread of prostate cancer among men participating in a phase 2 clinical trial exploring food as medicine , suggests a new study led by a team ...
Subscribe to our Free Newsletters!
Disclaimer - All information and content on this site are for information and educational purposes only. The information should not be used for either diagnosis or treatment or both for any health related problem or disease. Always seek the advice of a qualified physician for medical diagnosis and treatment.
Full Disclaimer
Advertise with us | Medindia Copyright | Privacy Policy | Terms of Use © All Rights Reserved 1997 - 2024
Careers